Status:
WITHDRAWN
Study Evaluating Inhibitor Specificity in Hemophilia A
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Hemophilia A
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
This investigation will utilize a systematic determination of anti-FVIII antibody specificity in PTPs (\> 50 ED) with hemophilia A who have developed inhibitors in response to treatment with any FVIII...
Eligibility Criteria
Inclusion
- · Patients with moderate or severe congenital hemophilia A, a current FVIII inhibitor, who have taken at least two different FVIII products during their lifetime.
Exclusion
- Patients who have had an inhibitor prior to their current inhibitor.
- Patients with immune disorders.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00151385
Start Date
November 1 2005
End Date
October 1 2007
Last Update
June 28 2012
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Atlanta, Georgia, United States, 30322
2
Detroit, Michigan, United States, 48201
3
New Hyde Park, New York, United States, 11040
4
New York, New York, United States, 10021